Article

Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2

2025-10-07

Abstract excerpt

Hepatitis C continues to be a significant public health problem despite advancements in antiviral therapeutics. To eliminate this disease, an effective vaccine against new infections and re-infections is needed. However, to date only one Hepatitis C virus (HCV) envelope protein (E1E2) immunogen, developed by Chiron Inc., has been tested in a Phase I clinical trial (ClinicalTrials.gov identifier NCT00500747 ). To...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 24ad08de-e5b0-56d9-aa0a-8da430f2e5e2
DOI: 10.1101/2025.10.07.680784

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2DOI 10.1101/2025.10.07.680784Read

Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteinsSemantic proximity Read

Distinct mechanisms of antibody-mediated HCV neutralization revealed by nanobody-guided epitope mappingSemantic proximity Read

Structural and biochemical insights into HCV envelope proteins for germline-targeting vaccinesSemantic proximity Read

Genetic and structural insights into broad neutralization of hepatitis C virus by human V H 1-69 antibodiesSemantic proximity Read

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.Semantic proximity Read

Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteinsSemantic proximity Read

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potencySemantic proximity Read

Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?Semantic proximity Read

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.Semantic proximity Read

Structural Flexibility of a Conserved Antigenic Region in Hepatitis C Virus Glycoprotein E2 Recognized by Broadly Neutralizing AntibodiesSemantic proximity Read

Structural basis for broad neutralization of hepatitis C virus quasispecies.Semantic proximity Read

Interplay of Host and Viral Genetic Variations in Modulating Antibody Responses to Genotype 3a Hepatitis C Virus: Implications for Vaccine DesignSemantic proximity Read